Indoco Remedies Ltd.
Snapshot View

448.25 +6.40 ▲1.5%

30 July 2021, 04:00:00 P.M.
Volume: 4,997

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.indoco.com
Financial Indicators
Market Cap 4,142.16 Cr.
Earnings per share (EPS) 10.10 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 44.52 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 83.45 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.39 Calculated using Price: 449.50
Dividend Yield 0.07 Period Ending 2020-03
No. of Shares Subscribed 9.22 Cr. 92,150,355 Shares
FaceValue 2
Company Profile

Indoco Remedies Limited is a Public Limited Company domiciled in India and incorporated under the provision of the Companies Act, VII of 1913. Its Shares are listed on two stock exchanges in India i.e Bombay Stock Exchange and National Stock Exchange. The company has decades of presence in the Indian Pharma market and a strong foothold in the international market.

Indoco has strengthened its wings in the international markets and offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide. The company has a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs).

Expertise in Research & Development, backward integration in API in select products, own CRO set-up, excellence in Finished Dosages manufacturing and a strong customer base will ensure consistent growth in the Company’s Domestic, as well as International business.

Business area of the company

Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company caters to both domestic and International markets.

Awards and Accolades

Patent Award

  • Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents - Diclofenac & Quetiapine
  • Indoco wins the IDMA Formulations Patent Award 2017-18 for 1 International and 2 Indian patents -Olopatadine, Gliclazide & Brinzolamide Ophthalmic Solution
  • Indoco receives the 'IDMA Best Patent Award' for four API Process Patents in 2017
  • Indoco Honoured with the 'IDMA Best Patent Award' for Three International Patents in 2016
  • Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category in 2016
  • Indoco receives European Patent approval for Lacosamide
  • Indoco honoured with 'Certificate of Appreciation' (Bulk Drugs) in 2015
  • Indoco wins 'Patent Appreciation Award' at 52nd IDMA Award Function in 2014

Awards

  • Rajhans Pratisthan Award 2017 for Mr. Suresh G. Kare and Indoco for commendable CSR initiatives carried out under the banner 'SUMATI SANGOPAN'
  • Mr. Suresh G. Kare receives 'The Pride of Goa' Award 2016 by the Goa Chamber of Commerce & Industry
  • Mr. Suresh G. Kare honoured with 'Lifetime Achievement Award' at the hands of The Chief Minister of Goa in 2016
  • Mr. Suresh G. Kare honoured with Udyogshree Life Time Achievement Award by Hon'ble Defence Minister, Mr. Manohar Parrikar in 2013
  • Mr. Suresh G. Kare received the prestigious Excellence Award-2004 from Pharma Business And Technology.
  • Ms. Aditi Kare Panandikar receives the 'Leader of the Year' Award at the UBM India Pharma Awards in 2016
  • Ms. Aditi Kare Panandikar receives the 'Businesswoman of the Year' award at the Business Goa Awards for Corporate Excellence in 2016
  • Ms. Aditi Kare Panandikar received the 2015 Jack L. Beal Post-baccalaureate Alumni Award from 'The Ohio State University College of Pharmacy' in USA

Goa Plant I Award

  • The Solid Dosage Forms and Externals Facility received the IDMA Quality Excellence Awards 2008 - Silver Award, for the third time.
  • The Solid Dosage Forms and Externals Facility received the IDMA Quality Excellence Awards 2003 - Formulations - Gold Award, second time since commissioned in 1997.

Goa Plant II Award

  • The Sterile Facility received the IDMA Quality Excellence Awards 2008 - Gold Award, for the third time.
  • The Sterile Facility for Injectibles and Ophthalmics received the IDMA Quality Excellence Awards 2003 - Formulations - Silver Award.

Milestone

1993

  • R&D recognized by DSIR

1997

  • Commencement of production in Goa Plant I

1999

  • New Corporate Office at Indoco House
  • Acquisition of Warren. Indoco makes presence in Ophthalmic & Dental Segments
  • Turnover crosses Rs 100 crore

2002

  • State-of-the-art sterile facility, Plant II commissioned at Verna Goa

2003

  • UK-MHRA approval for the Solid Dosage facility at Plant I
  • Exports to regulated markets commence
  • First contract for Dossier Development with European company
  • Domestic Marketing makes a foray into the lifestyle segment

2004

  • First Contract for Development services with US Company
  • Karvol brand acquisition from Solvay Pharmaceuticals Pvt. Ltd
  • Four Patent applications filed
  • Company jumps five ranks in two years in the ORG-IMS Retail Audit

2005

  • First ANDA filed on the basis of Exhibit batches manufactured in our sterile facility in Goa
  • Development Contracts for injectable products signed with a US Company
  • Tablet capacity doubled by commissioning an extended facility in the existing UK-MHRA approved plant
  • Shares of the Company listed on BSE and NSE

2006

  • US-FDA approval for Ophthalmic facility, Plant-II in GOA
  • Contract signed for supply of 18 generic products to German Market
  • 2 ANDAs filed with USFDA
  • Commencement of liquid manufacturing facility at Baddi, Himachal Pradesh
  • New R&D Centre at Rabale, near Mumbai becomes functional
  • Solid Dosage facility at Goa Plant I re-inspected & approved by UK-MHRA
  • UK-MHRA approval for Creams & Ointments facility
  • Darmstadt-Germany approves our Goa facility for Solid Dosage manufacturing
  • Acquisition of LaNOVA Chem Pvt. Ltd. with its brand new API manufacturing facility of international standards
  • Launch of Surge - a specialty marketing division

2007

  • ANVISA (Brazil) approval for the Solid Dosage facility at GOA Plant I
  • Commencement of exports to the US markets
  • Launch of Warren-Excel and Spera - two specialty marketing divisions

2008

  • IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award
  • TGA (Australia) approval for the Solid Dosage, Liquid Orals and Creams &Ointments Dosage forms at GOA Plant I
  • First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA
  • Successfully faced Slovenia audit for the Solid Oral Dosage forms at Baddi Plant
  • MCC (South Africa) approval for the Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II

2009

  • UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant
  • Export sales exceeded Rs. 1 Billion in the FY 08-09
  • Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area

2010

  • Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia
  • Indoco Remedies licenses out technology to Watson Pharmaceuticals Inc. USA. Under the terms of profit sharing agreement, Indoco will develop, manufacture and supply a basket of sterile products to Watson for the US market

2011

  • Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations

2012

  • Indoco announced the signing of an agreement with DSM, a € 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO
  • Innovation in Quality Award at CPhI Pharma Awards

2014

  • Inauguration of New GLP Analytical facility for Formulation
  • US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa
  • IDMA Best Patent Award for Tazarotene & Adapalene

2015

  • Indoco wins IDMA Patent Appreciation Award for Betaxolol
  • Indoco acquires Piramal's Clinical Research division

2016

  • Indoco Honoured with the IDMA Best Patent Award for Three International Patents
  • Indoco achieves a milestone of Rs1000 crore
  • Indoco acquires Oral Solid Dosage manufacturing facility in Baddi from Micro Labs Ltd., Bangalore
  • Indoco's Allopurinol ANDA gets USFDA approval
  • Indoco climbs 187 ranks up - Fortune India
  • Indoco receives USFDA approval for solid dosages Plant I in Goa
  • Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category

2017

  • Indoco receives the Express Pharma Export Excellence Award 2017
  • Indoco receives UKMHRA approval for solid dosages Plant I in Goa
  • Indoco receives the IDMA Best Patent Award for four API Process Patents
  • Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO)

2018

  • Indoco commissions New API manufacturing facility at Patalganga
  • Indoco's Goa Plant II & III clears USFDA inspection
  • Indoco's API manufacturing facilities at Patalganga and Rabale successfully clear USFDA inspection
  • Indoco's API Patalganga site receives Renewed Accreditation Certificate from The Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Indoco receives the IDMA Best Indian Patent Award for five API Process Patents
  • Indoco's Goa plant III receives EU GMP certification

2019

  • Indoco's Clinical Research Organisation receives zero 483s from USFDA
  • Indoco's stalwart brand CYCLOPAM crosses Rs 100 crore sales (as per IMS)
  • Indoco successfully completes UK-MHRA inspection at Goa Plant II
  • UK-MHRA reinstates full GMP status for Indoco's Goa Plant I
  • USFDA clears Indoco's Goa Plant II & III
  • Indoco gets European Patent Grant for unique process of Brinzolamide Eye Drops
  • Indoco wins the IDMA Formulations Patent Award 2017-18 for 2 International and 1 Indian patent
  • Indoco's new solid dosages facility at Baddi receives UK-MHRA approva
  • Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA Inspection

2020

  • Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg
  • Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents - Diclofenac & Quetiapine
  • Olopatadine ANDA filed from Indoco's Goa Plant II receives USFDA approval
  • AnaCipher Clinical Research receives BE study approval from WHO
  • First consignment of Glycopyrrolate Injection dispatched from Goa Plant II for launch in USA
  • Indoco receives USFDA approval for Succinylcholine Chloride Injection USP
  • Indoco receives USFDA approval for Olanzapine Tablets

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.45%
1 Week
+1.07%
1 Month
+8.48%
3 Month
+36.52%
6 Month
+49.29%
1 Year
+109.95%
2 Year
+185.96%
5 Year
+45.32%
9 years 2006-06 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 16.96 13.98 13.32 16.97 14.96 12.55 6.21 -0.43 3.60
Return on Capital Employed (%) 21.31 18.33 16.84 20.63 16.72 11.80 7.62 1.23 5.78
Return on Assets (%) 10.57 8.53 8.17 10.52 9.15 7.22 3.42 -0.24 1.96

Balance Sheet View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 414 457 519 577 651 675 661 680
Non Curr. Liab. 78 70 65 66 147 125 116 101
Curr. Liab. 199 202 262 303 390 417 446 459
Minority Int. 0 0
Equity & Liab. 692 729 846 946 1,189 1,218 1,223 1,240
Non Curr. Assets 416 425 460 481 617 679 684 676
Curr. Assets 276 305 385 465 572 539 538 563
Misc. Exp. not W/O
Total Assets 692 729 846 946 1,189 1,218 1,223 1,240

Profit Loss View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 631 733 857 1,008 1,075 1,042 968 1,107
Other Income 2 4 2 4 6 8 7 5
Total Income 632 737 859 1,012 1,081 1,050 975 1,111
Total Expenditure -538 -614 -692 -840 -920 -910 -892 -986
PBIDT 94 122 167 172 160 140 83 126
Interest -22 -19 -11 -12 -6 -24 -21 -26
Depreciation -24 -31 -47 -61 -63 -68 -72 -71
Taxation -6 -14 -27 -17 -14 -7 6 -4
Exceptional Items
PAT 43 58 83 82 77 41 -3 24

Cash Flow View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 69 99 109 112 89 123 132 123
Cash Fr. Inv. -43 -41 -88 -111 -171 -135 -104 -56
Cash Fr. Finan. -24 -59 -20 -2 132 -39 -16 -64
Net Change 2 -1 1 0 50 -51 12 3
Cash & Cash Eqvt 11 10 10 10 60 9 21 24

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 58.68 58.69 58.69 58.69 58.69 58.69 58.69 58.69 58.54
Public 41.32 41.31 41.31 41.31 41.31 41.31 41.31 41.31 41.46
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
SCHEDULE OF CONCALL MEETING {UNDER REG 30 -(LODR)}
SCHEDULE OF CONCALL MEETING
Tue, 27 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
INTIMATION UNDER REG 39(3) OF SEBI (LODR) 2015
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Credit Rating
Revised Credit rating by ICRA

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%